LAMINAR PHARMACEUTICALS is a pioneering biopharmaceutical company focused on drug discovery, rational design and early clinical development. All of these drugs are based on a novel therapeutic approach: Membrane Lipid Therapy (MLT) or, in short, melitherapy, which focuses on membrane lipids instead of acting directly on proteins or DNA. Like most medicines do.
LAMINAR was born in 2006 as an entity derived from the University of the Balearic Islands (UIB) in Mallorca, Spain. LAMINAR's goal is for melitherapy drugs to become global reference treatments for serious diseases with unmet medical needs such as glioblastoma and other aggressive cancers, as well as neurodegenerative, metabolic and inflammatory diseases.
Laminar is the first company that has managed to take a product patented in a Spanish University to the last phases of a clinical trial, LAM561. This compound is a synthetic lipid derivative that can be administered orally, with an outstanding safety profile and that presents promising results in patients with solid tumors and brain tumors such as glioblastoma multiforme (GBM), the most common and aggressive brain tumor without therapeutic solutions. with a life expectancy of patients currently between 14 and 16 months. This compound is in the last phase of clinical studies, phase IIB/III, for patients newly diagnosed with glioblastoma multiforme. This trial is pivotal for the European Medicines Agency (EMA) for its conditional approval as a reference drug for GBM, which LAMINAR hopes to be able to apply for in Q2/Q3 2024.
LAMINAR has a broad portfolio of growing projects. LAM561 is being developed for GBM but has shown preliminary results in other types of solid tumors, so we expect a future expansion of its indications. LAMINAR has other molecules in more initial development on the verge of entering clinical studies: LAM226 is a modified natural fatty acid (derived from DHA) that acts selectively in neurons, due to the specific omega-3 transporters present in the membranes. neuronal. In studies with mouse models of Alzheimer's disease, this drug has shown a recovery of cognitive abilities and biomarkers of a healthy brain. LAM204 is a derivative of a polyunsaturated fatty acid that has demonstrated a notable anti-inflammatory effect in laboratory studies with animal models. Its efficacy is similar to that of steroid compounds, although its non-steroidal structure suggests less toxicity, so this aspect has initially been evaluated in preliminary studies with zebrafish, flies and mice. There has been a collaboration with an external group of researchers (from the University of León, Spain) to explore the possible effect of LAM2014 in an animal model of ischemic injury after stroke, with promising results. In addition, other LAMINAR molecules are being developed by Spanish companies, which have successfully passed phase 2 of clinical trials, such as ABTL0812 developed by Ability Pharmaceuticals.
LAMINAR has offices in Spain (Palma de Mallorca) and the United States (Boston).
Pablo Escribá. Chief Executive Officer (CEO)
Victoria Lladó. General Manager USA.
David Roberto. Chief Financial Officer (CFO).
Paula Fernández. Chief Scientific Director (CSO).
Adrian McNicholl. Head of Clinical Operations (CCO).
Catalina Ana Rosselló. Head of Quality.
Antonio J. Gonzalez. Administrative Managing Director.
Teresa Escudero. Project Manager.
Jordi Ferrá. Clinical Program Manager.
Javier Fernandez. Business Development Manager.
Noelia Rocha. Financial Controller.
Bernardo Villalonga. Accounting responsible
LAMINAR is a clinical-stage biopharmaceutical company that is pioneering the use of melitherapy, or Membrane Lipid Therapy (MLT). This targets membrane lipids rather than acting directly on proteins or DNA as most medicines do. All our compounds are synthetic lipids.
INNOVATION. For more than 20 years, the founders of LAMINAR have laid the foundations to understand how lipid metabolism affects different pathologies. Thanks to this, lipid compounds can now be developed for various diseases such as cancer, Alzheimer's, inflammation, obesity...
QUALITY OF LIFE. With 3 phase 2 studies completed by LAMINAR molecules, the results in terms of safety and toxicity are surprising, with no serious adverse effects associated with LAM561, something extraordinarily rare for an anti-tumor compound.
Pablo Escribá. Chief Executive Officer (CEO)
Victoria Lladó. General Manager USA.
David Roberto. Chief Financial Officer (CFO).
Paula Fernández. Chief Scientific Director (CSO).
Adrian McNicholl. Head of Clinical Operations (CCO).
Catalina Ana Rosselló. Head of Quality.
Antonio J. Gonzalez. Administrative Managing Director.
Teresa Escudero. Project Manager.
Jordi Ferrá. Clinical Program Manager.
Javier Fernandez. Business Development Manager.
Noelia Rocha. Financial Controller.
Bernardo Villalonga. Accounting responsible
N/A
Laminar Pharma opens a new seek capital round of up to seven million euros
Laminar Pharma
Laminar Pharmaceuticals S.A. receives recommendation from the Independent Data Monitoring Committee to advance to the next stage of CLINGLIO, the phase 2b/3 Clinical Trial of LAM561 in combination with RT and TMZ for adults with newly diagnosed glioblastoma.
Laminar Pharma
Laminar Pharma y el viaje de un biofármaco que ha cautivado a más de 2.350 accionistas
Laminar Pharma
Laminar Pharma, premiada por La Razón en los Premios a la excelencia empresarial en plena ronda de ampliación de capital
Laminar Pharma
Laminar Pharma abre una nueva ronda de financiación de ocho millones
Laminar Pharma
Laminar Pharma capta 8,8 millones para luchar contra el tumor cerebral
Laminar Pharma
